1. Home
  2. MRVI vs TRDA Comparison

MRVI vs TRDA Comparison

Compare MRVI & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRVI
  • TRDA
  • Stock Information
  • Founded
  • MRVI 2014
  • TRDA 2016
  • Country
  • MRVI United States
  • TRDA United States
  • Employees
  • MRVI N/A
  • TRDA N/A
  • Industry
  • MRVI Biotechnology: Pharmaceutical Preparations
  • TRDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRVI Health Care
  • TRDA Health Care
  • Exchange
  • MRVI Nasdaq
  • TRDA Nasdaq
  • Market Cap
  • MRVI 262.9M
  • TRDA 502.9M
  • IPO Year
  • MRVI 2020
  • TRDA 2021
  • Fundamental
  • Price
  • MRVI $2.05
  • TRDA $8.84
  • Analyst Decision
  • MRVI Hold
  • TRDA Strong Buy
  • Analyst Count
  • MRVI 9
  • TRDA 3
  • Target Price
  • MRVI $6.54
  • TRDA $25.67
  • AVG Volume (30 Days)
  • MRVI 2.6M
  • TRDA 181.1K
  • Earning Date
  • MRVI 05-07-2025
  • TRDA 05-06-2025
  • Dividend Yield
  • MRVI N/A
  • TRDA N/A
  • EPS Growth
  • MRVI N/A
  • TRDA N/A
  • EPS
  • MRVI N/A
  • TRDA 1.68
  • Revenue
  • MRVI $259,185,000.00
  • TRDA $210,782,000.00
  • Revenue This Year
  • MRVI N/A
  • TRDA N/A
  • Revenue Next Year
  • MRVI $14.23
  • TRDA N/A
  • P/E Ratio
  • MRVI N/A
  • TRDA $5.26
  • Revenue Growth
  • MRVI N/A
  • TRDA 63.38
  • 52 Week Low
  • MRVI $1.67
  • TRDA $7.10
  • 52 Week High
  • MRVI $11.56
  • TRDA $21.79
  • Technical
  • Relative Strength Index (RSI)
  • MRVI 44.60
  • TRDA 47.88
  • Support Level
  • MRVI $1.67
  • TRDA $7.56
  • Resistance Level
  • MRVI $2.21
  • TRDA $9.34
  • Average True Range (ATR)
  • MRVI 0.16
  • TRDA 0.66
  • MACD
  • MRVI 0.08
  • TRDA 0.24
  • Stochastic Oscillator
  • MRVI 70.37
  • TRDA 77.54

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Share on Social Networks: